Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
HIPEC with Gemcitabine for Pancreatic Adenocarcinoma
NCT02863471Phase 2Unknown
- Sponsor
- University Hospital Tübingen
- Start
- Jan 2016
- Primary completion
- Jul 2018
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of gemcitabine in pancreatic adenocarcinoma (PDAC), sponsored by University Hospital Tübingen. Status: unknown.
02
Drugs
gemcitabine
03
Conditions
pancreatic adenocarcinoma (PDAC)
Beyond the preview
Go deeper on NCT02863471.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02863471.